Combination therapy for recurrent ovarian, fallopian tube, or peritoneal cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs—benmelstobart (an immunotherapy), anlotinib (a targeted therapy that blocks blood vessel growth to tumors), and low-dose cyclophosphamide (a chemotherapy drug)—to see if they can shrink tumors or slow down cancer in people with recurrent ovarian, fallopian tube, or peritoneal cancer. The goal is to find a new treatment option for those whose cancer has returned despite previous therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and are in generally good health (ECOG 0-1).
- You have recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (common types like serous, endometrioid, clear cell, mucinous, or undifferentiated).
- You have at least one tumor that can be measured on a scan (CT or MRI).
- You must be willing to have a biopsy (tumor sample) before starting and after 3 cycles of treatment.
- Your cancer may have come back within 6 months of platinum treatment (platinum-resistant), or if it came back later than 6 months, you cannot receive platinum again due to side effects, allergies, or refusal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs — a chemotherapy called liposomal irinotecan and an immunotherapy drug called enlonstobart — for women whose ovarian cancer has stopped responding to platinum-based chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a combination of three drugs — liposomal irinotecan (a type of chemotherapy), sintilimab (an immunotherapy that helps your immune system fight cancer), and anlotinib (a targeted therapy that blocks blood vessels feeding the tumor) — for women with ovarian clear cell carcinoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink or control the cancer better than existing options.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.